Table 2 Multivariate analysis on all patients: effect of GVHD prophylaxis on outcomes.

From: Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)

PT-Cy + MMF plus

Relapse

NRM

LFS

OS

GRFS

Tacrolimus vs. Cyclosporine Aa

1.07 (0.84–1.36)

0.87 (0.67–1.14)

0.95 (0.8–1.13)

0.97 (0.81–1.17)

0.97 (0.82–1.14)

PT-Cy + MMF plus

Acute GVHD II–IV

Acute GVHD III-IV

Chronic GVHD

Extensive chronic GVHD

 

Tacrolimus vs. Cyclosporine Aa

0.84 (0.64–1.1)

0.63 (0.43–0.93)

1.24 (0.97–1.58)

1.13 (0.75–1.7)

 
  1. aAll results are given as hazard ratios (95% CI).
  2. The bold value indicates statistical significance, with a p-value less than 0.05.
  3. PT-Cy post-transplant cyclophosphamide, MMF mycophenolate mofetil, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, GRFS grade III-IV acute GVHD or severe chronic GVHD, relapse-free survival, GVHD graft-versus-host disease.
Back to article page